- Harrow (HROW, Financial) expands its VEVYE® Access for All program to include over 25,000 Klarity-C patients.
- The FDA-approved cyclosporine ophthalmic solution, VEVYE, is available at $59 per bottle for eligible patients.
- The program features easy prescription transfer, no prior authorization, free delivery, and a money-back guarantee.
Harrow (HROW), a notable North American eyecare pharmaceutical company, has announced the expansion of its VEVYE® Access for All program. This expansion now includes patients currently using Klarity-C Drops®, allowing them to convert their prescriptions to VEVYE, an FDA-approved cyclosporine ophthalmic solution 0.1% for treating dry eye disease. Eligible patients can access VEVYE at a competitive rate of $59 per bottle, including refills.
The initiative, which is set to benefit more than 25,000 patients across the United States, aims to simplify and enhance patient experiences by removing typical access barriers. The program effectively eliminates the need for prior authorization and addresses reimbursement delays. Additionally, the offering includes free home delivery and a money-back guarantee, ensuring patient satisfaction and convenience.
Doctors prescribing Klarity-C can seamlessly transition prescriptions to VEVYE via PhilRx's platform, which takes under five minutes, thus reducing administrative burdens. Patients have the choice to either use their insurance coverage or opt for Harrow's straightforward cash pricing, further enhancing accessibility and affordability.
Mark L. Baum, CEO of Harrow, emphasized the simplicity and patient-centric focus of the program, stating that it provides a straightforward, cost-effective option for both patients and healthcare providers, devoid of insurance hurdles. This strategic expansion not only supports better patient outcomes but also promotes transparency and accessibility in the treatment of dry eye disease.
